Osteoporosis drug developer Radius Health Inc. has withdrawn its registration for an initial public offering, and is likely to pursue additional private funding to fund late-stage trials for its lead program.
After Canceling IPO, Radius May Tap Institutional Investors
With its IPO withdrawn, osteoporosis drug developer Radius Therapeutics is likely to seek funding from institutional backers. The company has just enough cash to last it through the first quarter, with big costs for a Phase III trial in the works.